Asian Pacific Journal of Cancer Prevention最新文献

{"title":"Combined Circulating miR-17-5p and Heat Shock Proteins as Diagnostic Biomarkers for Colorectal Cancer Progression.","authors":"Hamdi M Abo-Alazm, Mohamed Y Nasr, Khalid Bassiouny, Ahmed K Zaki, Noha Rashad, Ahmed M Tabl, Hany Khalil","doi":"10.31557/APJCP.2026.27.9.3421","DOIUrl":"https://doi.org/10.31557/APJCP.2026.27.9.3421","url":null,"abstract":"<p><strong>Objectives: </strong>Colorectal cancer (CRC) remains a significant global health challenge, and early diagnosis is essential for improving patient survival and treatment outcomes. Currently used serum biomarkers, including carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), suffer from limited sensitivity and specificity, particularly in early-stage disease, which restricts their clinical utility. Therefore, identifying more reliable biomarkers for CRC detection and monitoring is urgently needed. This study investigated the diagnostic value of microRNA-17-5p (miR-17-5p) and selected heat shock proteins (HSPs) as potential non-invasive biomarkers for CRC.</p><p><strong>Methods: </strong>The study included patients with confirmed CRC, individuals with benign colorectal diseases, and healthy control subjects. Plasma levels of miR-17-5p and relative gene expression of HSPs were quantified in obtained samples using quantitative real-time PCR, while circulating HSP concentrations were measured using enzyme-linked immunosorbent assay (ELISA).</p><p><strong>Results: </strong>The results demonstrated a marked upregulation of miR-17-5p in CRC patients, showing a six-fold increase compared with healthy controls. Patients with benign colorectal disorders exhibited a moderate two-fold increase. Similarly, HSP40 and HSP90 expression levels were significantly elevated in CRC patients, whereas their levels were reduced in benign colorectal cases relative to healthy individuals. In contrast, HSP70 expression was significantly decreased in both CRC and benign colorectal patients compared with controls. Overall, miR-17-5p and HSPs showed superior diagnostic accuracy compared with conventional biomarkers. Notably, combined biomarker analysis significantly enhanced sensitivity and specificity in distinguishing CRC from benign colorectal conditions. Among the evaluated markers, miR-17-5p in combination with HSP40 and HSP90 demonstrated the strongest diagnostic performance.</p><p><strong>Conclusion: </strong>These findings suggest that this biomarker panel holds promise for CRC diagnosis, prognosis, and potential therapeutic targeting, offering improved strategies for clinical management.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 9","pages":"3421-3429"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149076915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Nutritional Index Is Associated With Gastrointestinal Symptom Severity in Patients Receiving Chemotherapy for Gastrointestinal Cancer: A Cross-Sectional Study.","authors":"Yasemin Ciraci Yasar, Mehtap Tan, Mehmet Bilici, Zekiye Demir","doi":"10.31557/APJCP.2026.27.9.3441","DOIUrl":"10.31557/APJCP.2026.27.9.3441","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the relationship between the Prognostic Nutritional Index (PNI) and chemotherapy-related gastrointestinal (GI) symptom severity in patients with GI cancer.</p><p><strong>Methods: </strong>This observational cross-sectional study included 262 adult patients with GI cancer receiving chemotherapy at a research hospital in eastern Türkiye. Nutritional status was assessed using the Prognostic Nutritional Index, calculated from serum albumin levels and lymphocyte counts obtained prior to chemotherapy cycles. Gastrointestinal symptom burden was evaluated using the Gastrointestinal Symptom Rating Scale (GSRS). Descriptive statistics, group comparisons, and correlation analyses were performed to evaluate associations between clinical variables, PNI, and GSRS scores.</p><p><strong>Result: </strong>The mean PNI score was 39.34 ± 12.31, and nearly half of the participants were classified as at risk for malnutrition based on sample-specific cut-off values. The mean total GSRS score was 36.23 ± 12.06, indicating mild-to-moderate symptom severity. GSRS scores were significantly higher among patients with advanced disease stages and lower PNI values. Correlation analysis revealed a statistically significant negative association between PNI and GSRS scores (r = -0.239, p < 0.05), demonstrating that poorer nutritional status was associated with greater gastrointestinal symptom severity. In the multiple linear regression analysis, it was determined that cancer stage and chemotherapy protocol had significant effects on PNI and GSRS scores (p<0.05).</p><p><strong>Conclusion: </strong>This study demonstrates that lower PNI is linked to greater gastrointestinal symptom severity, underscoring the need to integrate routine nutritional evaluation with gastrointestinal symptom monitoring in GI cancer care.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 9","pages":"3441-3448"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149076792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-Authorization Safety Study of Papilloguard (A Domestically Manufactured Bivalent (16,18) HPV Vaccine in Iran.","authors":"Mojgan Karimi Zarchi, Mina Ebrahimi","doi":"10.31557/APJCP.2026.27.9.3161","DOIUrl":"https://doi.org/10.31557/APJCP.2026.27.9.3161","url":null,"abstract":"<p><strong>Background: </strong>In recent years, various vaccines, including Papilloguard, have been introduced to prevent transmission of this virus. This vaccine has shown good immunogenicity and efficacy profile in phase III study; however, its safety remains controversial. This study aimed to investigate the complications and adverse events associated with the Papilloguard vaccine in the Iranian population.</p><p><strong>Methods: </strong>In this survey study, 1,028 volunteers (690 (67.1%) female and 338 (32.9%) males, mean age 33.8±7.01), who had received the Papilloguard vaccine and whose basic information was recorded in the Papilloguard vaccine registration system by call center team of Arta Pharmed Company (Tehran, Iran) were examined. Cumulative vaccine-related complications were assessed and recorded by Arta Pharmed Company's call center team 7 days, 1 month, and 6 months after receiving each dose of vaccine during the 6 months following vaccination. Patient evaluations were conducted over the phone. Any complication leading to hospitalization or requiring medical interventions was defined as a serious complication.</p><p><strong>Result: </strong>The cumulative incidence of at least one complication immediately after injection, 7 days, 1 month, and 6 months after injection was reported in 272 (26.5%), 101 (9.8%), 74 (7.2%), and 29 (2.8%) of the participants, respectively. Post-injection pain was the most common complication after vaccination, 227 (22.1%). The cumulative incidence of injection site pain 7 days, 1 month, and 6 months after injection was 8.4%, 5.7%, and 0.7%, respectively. In terms of severity of complications, complications were reported as mild in 253 (24.6%), moderate in 15 (1.5%), and severe in 4 (0.4%) recipients. Only 0.4% of recipients experienced severe complications.</p><p><strong>Conclusion: </strong>In a mid-term follow-up, in the Iranian population, Papilloguard vaccine had few side effects and was well tolerated. Papilloguard vaccine can be included in national vaccination guidelines for the prevention of HPV and its consequences.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 9","pages":"3161-3167"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149076664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nurses' Experiences of Grief Care for Terminally Ill Cancer Patients and Their Families: A Qualitative Study.","authors":"Ahmad Mahmoud Saleh","doi":"10.31557/APJCP.2026.27.9.3299","DOIUrl":"https://doi.org/10.31557/APJCP.2026.27.9.3299","url":null,"abstract":"<p><strong>Background: </strong>Grief care is a vital yet emotionally demanding component of end-of-life nursing for patients with terminal cancer, with significant implications for family and community well-being. In Jordanian private hospitals, cultural sensitivities surrounding death and limited formal grief-care education may challenge nurses' ability to support patients and families effectively, with implications for sustainable healthcare practice.</p><p><strong>Purpose: </strong>This study explored nurses' experiences of grief care work with dying patients and their families from a community health nursing perspective in a Jordanian private hospital and considered its relevance to the Sustainable Development Goals (SDGs).</p><p><strong>Methods: </strong>A qualitative study using semi-structured, in-depth interviews was conducted. Twelve nurses with experience caring for terminally ill cancer patients in a Jordanian private hospital participated. Data were analyzed using thematic analysis.</p><p><strong>Results: </strong>Results: Twelve nurses participated in the study. Five themes emerged across the periods before, during, and after patient death: (1) hardships and efforts of patients and families in facing death; (2) family reactions during the dying process; (3) providing compassionate nursing care; (4) nurses' experiences in grief care; and (5) nurses' personal and professional transformation. Ten subthemes captured key aspects of these experiences, including patient suffering, family support, stress and acceptance, emotional expression, practical care, nurses' concerns for the bereaved, feelings of helplessness, challenges in grief care, needs for future support, and professional growth. Nurses reported experiencing emotional burden, communication challenges, and moral distress, yet demonstrated resilience, empathy, and development of both personal and professional coping strategies.</p><p><strong>Conclusion: </strong>Cultural barriers and limited grief-care training hinder effective end-of-life support. Integrating structured grief-care education, reflective practice, and psychological support into nursing education and hospital systems and community-oriented care models can enhance care quality and promote nurses' well-being, contributing to SDG 3 (Good Health and Well-Being), SDG 4 (Quality Education), and SDG 8 (Decent Work and Economic Growth).</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 9","pages":"3299-3305"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149076671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Therapeutic Potential of Ginkgo biloba: Phytochemical Composition, Antibacterial Activity Against Multidrug-Resistant Pathogens, and Modulation of Cancer Signaling.","authors":"Shahad Basil Ismael, Noor Dheyaa Hameed, Nawar Bahaa Abdulsahib, Mayssaa E Abdalah, Ragheed Hussam Yousif, Majid S Jabir","doi":"10.31557/APJCP.2026.27.9.3431","DOIUrl":"https://doi.org/10.31557/APJCP.2026.27.9.3431","url":null,"abstract":"<p><strong>Objective: </strong>Evaluate the phytochemical composition of Ginkgo biloba methanolic extract and investigate its anticancer and antibacterial activity, along with exploring its potential molecular mechanism of action through molecular docking analysis.</p><p><strong>Methods: </strong>Phytochemical protocols including phenols, flavonoids and saponins were qualitatively evaluated. The anti-bacterial activity was tested versus G+ and G- bacteria using agar well diffusion method. Cytotoxic activity was investigated using the MTT assay on HepG2 (liver cancer), A549 (ling cancer) and WRL-68 (normal) cell lines. Additionally, molecular docking analysis was performed to evaluate the interaction between selected bioactive compounds and the Akt1 protein (PDB ID:2C6T).</p><p><strong>Results: </strong>The extract demonstrated high levels of total phenols (309.47 ± 4.21 mg GAE/g), total flavonoids (299.78 ± 14.81 mg/mL), and total saponins (137.76 ± 1.72 g/100 g). A significant antibacterial activity was observed in a concentration-dependent manner; the strongest effect was against Escherichia coli, showing inhibition zones ranging from 10 to 27 mm. The MTT assay showed a dose-dependent reduction in the viability of cancer cells, where HepG2 viability decreased from 92.28 ± 1.88% to 45.48 ± 2.61% (IC50 = 144.8 µg/mL), and A549 viability decreased from 93.17 ± 0.41% to 56.16 ± 3.56% (IC50 = 54.33 µg/mL). Meanwhile, lower cytotoxicity was observed in normal WRL-68 cells (IC50 = 145 µg/mL). Molecular docking analysis revealed favorable binding of Ginkgo phytochemicals to the Akt1 active site, with ginkgolide B showing the highest binding affinity (-7.19 kcal/mol), followed by isorhamnetin (-6.79 kcal/mol).</p><p><strong>Conclusion: </strong>Ginkgo biloba methanolic extract demonstrates significant antibacterial, antioxidant, and anticancer activities. These biological activities mostly arise from its rich phytochemical composition, particularly the bioactive constituents that may target key signaling pathways such as PI3K/Akt. Consistently, molecular docking analysis suggests a synergistic multi-compound mode of action, supporting the idea that Ginkgo biloba has the potential to serve as a valuable source for multi-target therapeutic development.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 9","pages":"3431-3439"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149076725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regional Differences in Cancer Research Trends in East and Southeast Asia Based on Analyses of the PubMed Registry.","authors":"SongYi Han, Tae-Min Kim","doi":"10.31557/APJCP.2026.27.9.3315","DOIUrl":"https://doi.org/10.31557/APJCP.2026.27.9.3315","url":null,"abstract":"<p><strong>Objective: </strong>Cancer represents a major and growing public health burden across Asia, yet cancer research capacity, priorities, and methodologies vary substantially between East Asia (EA) and Southeast Asia (SEA). How scientific activity has evolved across these regions over time remains incompletely characterized.</p><p><strong>Methods: </strong>We conducted a large-scale bibliometric and text-mining analysis of PubMed-indexed cancer-related publications from 2000 to 2025, covering 18 countries and territories in EA and SEA. Publication metadata, Medical Subject Headings (MeSH), author affiliations, and country information were systematically extracted and harmonized. Temporal publication trends were assessed using raw counts and GDP-normalized metrics. Tumor-type emphasis and methodological focus were examined using MeSH-based analyses. Latent research themes were identified using non-negative matrix factorization (NMF). International collaboration patterns were reconstructed through country-level co-affiliation networks across three time periods.</p><p><strong>Results: </strong>Cancer research output increased markedly across both regions, with EA accounting for substantially higher absolute publication volumes, driven primarily by China, Japan, and Korea. After normalization by GDP, several smaller but research-intensive systems-including Korea, Taiwan, Singapore, and Vietnam demonstrated high productivity relative to economic scale. Tumor-type analyses revealed strong alignment between research focus and regional cancer epidemiology, including liver and cholangiocarcinoma in SEA and gastric and lung cancer in EA. Methodological comparisons showed a clear regional divergence: EA research emphasized molecular, mechanistic, and translational approaches, whereas SEA research was enriched for cohort-based, epidemiologic, and public-health-oriented studies. Topic modeling and collaboration networks further highlighted complementary regional strengths and increasing global integration over time.</p><p><strong>Conclusions: </strong>Cancer research in EA and SEA has expanded and diversified over the past 25 years, reflecting regional differences in disease burden, infrastructure, and policy priorities. Our findings underscore the importance of targeted public health strategies, sustained investment in regionally relevant cancer research capacity, and strengthened international collaboration frameworks to promote more equitable and effective cancer control across Asia.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 9","pages":"3315-3324"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149076854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of S100A4, CA-12, CA-9, Annexin A1/A2, and Galectin-3 in Prostate Cancer: Diagnostic and Prognostic Implications.","authors":"Rahmi Aslan, Zübeyir Huyut, Muhammed Fatih Keleş, Nedim Bedir, Recep Eryılmaz, Mehmet Tahir Huyut, Murat Saygın, Murat Demir, Kerem Taken","doi":"10.31557/APJCP.2026.27.9.3281","DOIUrl":"https://doi.org/10.31557/APJCP.2026.27.9.3281","url":null,"abstract":"<p><strong>Objective: </strong>The limited specificity of prostate-specific antigen (PSA) increases the risk of unnecessary biopsies and overtreatment. This study aimed to evaluate the diagnostic and prognostic value of serum S100A4, along with CA-9, CA-12, Annexin A1/A2, and Galectin-3, in prostate cancer.</p><p><strong>Methods: </strong>This prospective case-control study, conducted between July 2024 and September 2025, included 80 patients with histopathologically confirmed prostate cancer and 40 age-matched healthy controls. Patients were stratified into low-risk (ISUP grades 1-2) and high-risk (ISUP ≥3) groups. Serum biomarker levels were measured using ELISA. Diagnostic and prognostic performance was assessed by receiver operating characteristic (ROC) analysis, with cut-off values determined using the Youden index. Logistic regression analyses were performed to identify independent biomarkers.</p><p><strong>Results: </strong>Serum CA-12 and CA-9 levels were significantly higher in prostate cancer patients than in controls (p = 0.004 and p = 0.032, respectively). Although S100A4 levels were lower in prostate cancer patients compared with controls, they were significantly higher in high-risk patients within the cancer cohort (p = 0.002). Logistic regression identified S100A4 (p = 0.032) and CA-12 (p = 0.004) as independent predictors of prostate cancer diagnosis. ROC analysis demonstrated excellent diagnostic accuracy for CA-12 (>52.9 ng/mL; AUC = 0.99) and S100A4 (<9.96 ng/mL; AUC = 0.98). For prognostic stratification, S100A4 (>8.27 ng/mL; AUC = 0.97) and CA-12 (>72.8 ng/mL; AUC = 0.91) effectively distinguished high-risk from low-risk disease.</p><p><strong>Conclusion: </strong>S100A4 and CA-12 exhibit strong diagnostic and prognostic performance in prostate cancer. When used alongside PSA, S100A4 and CA-12 may improve risk stratification in patients with suspected prostate cancer and help reduce unnecessary prostate biopsies.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 9","pages":"3281-3287"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149076717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Barriers and Facilitators of Cancer Screening Uptake in Meghalaya and Mizoram States under the National Programme for Prevention and Control of NCDs in India: A Mixed-methods Study.","authors":"Sutapa Biswas, Bobby Paul, Anushka Ghosh, Ranajit Mondal, Maqsood Siddiqi","doi":"10.31557/APJCP.2026.27.9.3465","DOIUrl":"https://doi.org/10.31557/APJCP.2026.27.9.3465","url":null,"abstract":"<p><strong>Objective: </strong>Cancer is a leading cause of both morbidity and mortality in India. In response, the government launched a national screening programme under the National Programme for Prevention and Control of Non-communicable Diseases (NPCDCS/NP-NCD). Despite comprehensive guidelines, screening rates remain very low. We conducted a field study in Meghalaya and Mizoram between 2021 and 2023 to identify barriers and facilitators to cancer screening uptake, involving a diverse group of stakeholders.</p><p><strong>Methods: </strong>The mixed-methods study included 420 frontline health workers (FLHWs), 38 government officials, 75 key informants from non-governmental organisations, and 244 community members. We employed purposive and snowball sampling methods to recruit a diverse group of participants for qualitative data collection. For quantitative data collection, we used a stratified random sampling technique. Data collection comprised surveys, in-depth interviews and free-listing in both physical and virtual settings. Quantitative data from FLHWs were statistically analysed, while qualitative data from other stakeholders were reviewed and thematically coded using Anthropac version 4.98.1/X, with graphical visualisation in ATLAS.ti.</p><p><strong>Results: </strong>Stakeholders highlighted critical barriers to cancer screening uptake. At the individual level, obstacles include fears of diagnosis. At the community level, lack of cancer awareness and social stigma persist. Healthcare facilities face challenges like infrequent cancer screenings and resource shortages. At the policy level, insufficient financial support and ineffective communication strategies were key issues. Stakeholders recommended innovative awareness campaigns, information sharing through community events and gram sabhas, and engagement of community leaders and NGOs. They also emphasised upgrading infrastructure, enhancing staff training and adding screening facilities in villages.</p><p><strong>Conclusion: </strong>The study offers a detailed analysis of barriers and facilitators to cancer screening uptake, as highlighted by a diverse group of stakeholders. Findings suggest that complex, multi-layered challenges require innovative communication strategies and systemic improvements to enhance participation in cancer screening within the NPCDCS/NP-NCD initiatives in Meghalaya and Mizoram.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 9","pages":"3465-3478"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149076773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate Cancer Epidemiology In A Central Asian Region After Discontinuation Of Screening: Population-Based Data From Abay, Kazakhstan (2020-2024).","authors":"Laura Zeinelova, Bayan Atantayeva, Bakytbek Apsalikov, Tolegen Kurmangaliyev, Mergyl Karipova, Erkezhan Ashimova, Sayat Tanatarov","doi":"10.31557/APJCP.2026.27.9.3393","DOIUrl":"https://doi.org/10.31557/APJCP.2026.27.9.3393","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer is one of the most common malignancies among men worldwide, with marked regional variability in incidence, mortality, and stage at diagnosis. Data from Central Asia remain limited, particularly in regions without organized prostate-specific antigen (PSA) screening programs. This study aimed to assess the epidemiology of prostate cancer in the Abay region of Kazakhstan during the post-screening period.</p><p><strong>Methods: </strong>A retrospective population-based descriptive study was conducted using official cancer registry data from the Abay region. All newly diagnosed prostate cancer cases (ICD-10 code C61) registered between 2020 and 2024 were included. Incidence, mortality, stage distribution at diagnosis, one-year lethality, prevalence, and the proportion of patients under ≥5-year follow-up in the cancer registry were analyzed using descriptive epidemiological methods. Year-to-year relative changes were used to describe temporal patterns in incidence and mortality.</p><p><strong>Results: </strong>A total of 260 new prostate cancer cases were registered during the study period. The incidence rate increased from 7.2 per 100,000 male population in 2020 to 9.2 per 100,000 in 2024, with a peak observed in 2023. In contrast, mortality declined steadily overall from 5.7 to 2.8 per 100,000 over the same period. Stage II disease predominated; however, advanced-stage cancer remained common. The proportion of stage IV disease ranged from 25.8% to 37.5%, indicating persistent late diagnosis. The proportion of patients registered in the cancer registry for ≥5 years increased from 42.1% to 56.4%, and prevalence rose from 55.4 to 63.6 per 100,000, reflecting the accumulation of patients under long-term observation.</p><p><strong>Conclusions: </strong>Despite increasing incidence, prostate cancer mortality in the Abay region declined during 2020-2024. However, the persistently high proportion of advanced-stage disease indicates substantial challenges in early detection in the absence of organized screening. These findings describe the current epidemiological profile of prostate cancer in a Central Asian region operating under opportunistic diagnostic practices.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 9","pages":"3393-3398"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149076786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"α-Chaconine as a Potential Inhibitor of Mutant Phosphatidylinositol 3-Kinase Alpha in Breast Cancer Stem Cells: Insights from Structure Prediction and Molecular Dynamics.","authors":"Bakti Wahyu Saputra, Navista Sri Octa Ujiantari, Badra Sanditya Rattyananda, Ratna Surya Alwi, Agustina Setiawati, Adam Hermawan","doi":"10.31557/APJCP.2026.27.9.3411","DOIUrl":"https://doi.org/10.31557/APJCP.2026.27.9.3411","url":null,"abstract":"<p><strong>Introduction: </strong>Breast cancer stem cells (BCSCs) promote chemoresistance and metastasis by activating aberrant signaling pathways such as phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt). α-Chaconine (CHA) is a steroidal glycoalkaloid that has demonstrated cytotoxic and antiproliferative activity in various cancer models, possibly through modulation of the PI3K/Akt pathway. However, its direct interaction with PI3Kα and related alterations has not yet been elucidated. This study aimed to assess CHA as a potential BCSC-targeting agent, particularly as a PI3K inhibitor targeting both wild-type and mutant PI3Kα, using an in silico approach.</p><p><strong>Methods: </strong>Mutation data were retrieved from cBioPortal and analyzed using MutPred2. SWISS-MODEL was used to generate homology models of the wild-type and mutant PI3Kα structures. Structural validation was performed using PROCHECK and ERRAT. Molecular docking was employed to evaluate the binding affinity of the PI3Kα-CHA complex. Molecular dynamics simulations were conducted to assess the stability of the interaction between CHA and PI3Kα.</p><p><strong>Results: </strong>Three PIK3CA mutations were identified as pathogenic: E542K, E545K, and H1047R. Molecular docking revealed a strong binding affinity of alpelisib to both wild-type and mutant (E542K, E545K, and H1047R) forms of p110 α. CHA exhibited the lowest binding energy with the H1047R mutant, with a docking score of -9.93 kcal/mol. Molecular dynamics simulations demonstrated stable interactions of alpelisib with wild-type, E542K, and E545K mutants, whereas CHA showed stable interaction only with the H1047R mutant. MM-PBSA calculations confirmed the lowest binding free energies for alpelisib-wild-type p110α and CHA-H1047R complexes, with values of -29.21 kcal/mol and -25.88 kcal/mol, respectively.</p><p><strong>Conclusion: </strong>These findings provide a basis for further in vitro and in vivo studies to evaluate CHA as a selective PI3K inhibitor targeting the H1047R PIK3CA mutation in breast cancer stem cells.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 9","pages":"3411-3419"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149076866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}